Protocol Ledger

NCT05642572 · Phase II · RECRUITING

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Interventional Phase II clinical trial protocol NCT05642572 sponsored by SWOG Cancer Research Network in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-05 Enrollment: 66 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05642572
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)66 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05642572
Protocol FieldVerified Registry Value
NCT IdentifierNCT05642572
Consolidated Lead SponsorSWOG Cancer Research Network
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment66 participants (ESTIMATED)
Registered Start Date2023-05-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI